Imunomodulatorji pri zdravljenju malignega melanoma

Povzetek

Ključne besede

Podatki

Jezik:	Slovenski jezik
Leto izida:	2013
Tipologija:	1.03 - Kratki znanstveni prispevek
Organizacija:	OI - Onkološki inštitut Ljubljana
UDK:	616.5
COBISS:	1682043
ISSN:	1408-1741
Matična publikacija:	Onkologija
Št. ogledov:	2265
Št. prenosov:	580
Ocena:	0 (0 glasov)
Metapodatki:

Ostali podatki

Sekundarni jezik:	Angleški jezik
Sekundarni naslov:	Imunomodulators in the treatment of malignant melanoma - case report
Sekundarni povzetek:	The incidence of melanoma is increasing, both in Slovenia and world-wide, more than any other form of cancer. According to the Cancer Registry of Slovenia, 415 patients were diagnosed with this disease in 2009 (1). Surgical removal of skin melanoma is the primary curative treatment for patients with early-stage disease. There are approximately 80% of such patients. In high-risk patients (around 10%), we also recommend treatment with high doses of interferon-α2b (2, 3). Metastatic melanoma is still an incurable disease with a 5-year survival of less than 5%. However, the prognosis for these patients has improved in the last few years, thanks to new developments in the field of systemic treatment. Besides standard treatment with systemic chemotherapy, new registered medicines are now also available with a different mechanism of action than chemotherapy, such as immunotherapy with the monoclonal antibody ipilimumab, BRAF inhibitors vemurafenib and dabrafenib, and MEK inhibitors (2, 3).
URN:	URN:NBN:SI
Strani:	str. 139-142, 158
Letnik:	ǂLetn. ǂ17
Zvezek:	ǂšt. ǂ2
Čas izdaje:	dec. 2013
ID:	10957274